Environmental, Social and Governance Report

Overview

The report is Xuanzhu Biopharmaceutical's first ESG report and covers 2025. It reports Scope 1 emissions of 12.74 tonnes CO2e, location-based Scope 2 emissions of 1,224.63 tonnes CO2e, and Scope 3 emissions of 212.02 tonnes CO2e. The company also reports that three proprietary Class 1 innovative drugs had received marketing approval by the end of the reporting period.

Document

Report type: Sustainability Report
Class: Dedicated
Scope: Full report
Fiscal year: 2025
Period: 1 January 2025 – 31 December 2025
Publication date: 30 March 2026
Language: English, Chinese
Pages
File size

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP
Other

Materiality

Assessment
Basis
Matrix

Assurance

Statement included

Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services